WO2011086001A1 - Anticorps pour le traitement du vhc - Google Patents

Anticorps pour le traitement du vhc Download PDF

Info

Publication number
WO2011086001A1
WO2011086001A1 PCT/EP2011/000157 EP2011000157W WO2011086001A1 WO 2011086001 A1 WO2011086001 A1 WO 2011086001A1 EP 2011000157 W EP2011000157 W EP 2011000157W WO 2011086001 A1 WO2011086001 A1 WO 2011086001A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
fragment
seq
domain
amino acid
Prior art date
Application number
PCT/EP2011/000157
Other languages
English (en)
Inventor
Riccardo Cortese
Alfredo Nicosia
Original Assignee
Cormus Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cormus Srl filed Critical Cormus Srl
Publication of WO2011086001A1 publication Critical patent/WO2011086001A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to novel scavenger receptor class B type 1 (SR-B1) specific antibodies and the use of SR-B1 specific antibodies in the treatment of Hepatitis C virus (HCV).
  • SR-B1 novel scavenger receptor class B type 1
  • HCV is a global blood-borne pathogen with 3% of the world's population chronically infected. Most infections are asymptomatic, but 60-to-80% of them become persistent and lead to severe fibrosis and cirrhosis, hepatic failure or hepatocellular carcinoma (HCC; see Shepard, C. W., L. Finelli, and M. J. Alter. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558-67; and Wasley, A., and M. J. Alter. 2000. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20: 1-16). Currently available therapies are limited and are expensive, often unsuccessful, and carry the risk of significant side effects. Thus, development of novel therapeutic approaches against HCV remains a high-priority. Targeting the early steps of HCV infection may represent a viable option and much effort is being devoted to uncovering the mechanism of viral attachment and entry.
  • HCV entry into target cells occurs after attachment to specific cellular receptors via its surface glycoproteins El and E2.
  • the molecules to which HCV initially bind might constitute a diverse collection of cellular proteins, carbohydrates, and lipids that concentrate viruses on the cell surface and determine to a large extent which cell types, tissues, and organisms HCV can infect.
  • the mannose binding C-type lectins, DC-SIGN and L-SIGN, and liver-specific glycosaminoglycans (GAGs) such as highly sulfated heparan sulfate proteoglycans (HSPGs) have been proposed as putative attachment factors for HCV (see e.g. Barth, H., et al., 2003, "Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulphate", J Biol Chem 278:41003-12).
  • L-SIGN is highly expressed in liver sinusoidal endothelial cells (LSEC), which are located in the wall of the liver sinusoids, but not in hepatocytes, while DC-SIGN is expressed in Kupffer cells, which are resident liver macrophages localized close to LSEC and hepatocytes. L-SIGN and DC-SIGN have been shown to capture and transmit HCV to hepatocytes, thereby facilitating receptor binding events.
  • LSEC liver sinusoidal endothelial cells
  • Kupffer cells which are resident liver macrophages localized close to LSEC and hepatocytes. L-SIGN and DC-SIGN have been shown to capture and transmit HCV to hepatocytes, thereby facilitating receptor binding events.
  • LDL-R low density lipoprotein receptor
  • SR-B1 scavenger receptor class B type 1
  • Scarselli E. et al, 2002.
  • the human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.
  • Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-5) and occludin (Ploss a. et al, 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature. 2009 Feb 12;457(7231):882-6).
  • CD81, CLDN1 and SR-B1 have been shown to play an essential role in HCV cell infection (Evans, M. J. et al. 2007.
  • Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-5; Piled, P., et al., 1998, "Binding of hepatitis C virus to CD81", Science 282:938-41 ; Scarselli, E. et al, 2002.
  • the human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21 :5017-5025; Zhang, J. et al 2004.
  • CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol 78: 1448-55). Previous data suggested that down-regulation of SR-B1 using an RNAi approach had almost no inhibitory effect on HCV infectivity despite efficient silencing of SR- Bl expression (see Voisset C, et al., 2005, J. Biol. Chem., 280: 7793-7799). Thus, in particular, CD81 appeared to be necessary for viral entry into hepatic cells via residues that are involved in virus/receptor interaction.
  • SR-Bl is a lipoprotein receptor of 509 amino acids with cytoplasmic C- and N- terminal domains separated by a large extracellular domain (see Acton, S. et al., 1996, "Identification of scavenger receptor SR-Bl as a high density lipoprotein receptor", Science 271 :518-20; and see also: Calvo, D., and M. A. Vega, 1993, "Identification, primary structure, and distribution of CLA-1, a novel member of the CD36/LIMPII gene family", J Biol. Chem. 268: 18929-35).
  • SR-Bl was originally identified as a putative receptor for HCV because it binds soluble E2 (sE2) through interaction with the E2 hypervariable region 1 (HVR1). This finding suggested that SR-Bl next to other receptors may function in HCV attachment to the target cell and, therefore it could act at the level of virus entry (Scarselli, E. et al, 2002.
  • the human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21 :5017-5025).
  • the inventors have generated new human monoclonal antibodies with an improved dissociation constant against SR-B 1 which unexpectedly were found to not only inhibit HCV entry, i.e. endocytosis, but in addition, also proved to be potent inhibitors of virus transmission from cell-to-cell.
  • novel anti-SR-Bl antibodies unexpectedly inhibited cell-to-cell spread these new antibodies are capable of blocking virus spread and expansion in vivo and, thus, can be used not only for prophylactic medical use against HCV but can also be used for therapy, e.g. to treat a HCV infection.
  • the antibodies of the present invention and fragments thereof are, thus, preferably administered to patients that already have contracted the HCV disease.
  • the antibody anti-SRBl mAb8 when used at a concentration of 0.008 ⁇ , was capable of reducing HCV infection by more than 50% (cf. Figure 5).
  • the present invention provides improved antibodies that can be used for the prevention and treatment of an HCV infection.
  • the present invention provides an antibody or fragment thereof, which binds to the scavenger receptor class B type 1 (S -B1).
  • the heavy chain of said antibody or fragment thereof comprises a CDR3 domain selected from a group of amino acid sequences consisting of SEQ ID NO: 13, 15, 17,
  • said CDR3 domain of the heavy chain may optionally comprise a single amino acid substitution, deletion, modification and/or insertion;
  • the light chain of said antibody or fragment thereof comprises a CDR3 domain selected from a group of amino acid sequences consisting of SEQ ID NO: 14, 16, 18,
  • said CDR3 domain of the light chain may optionally comprise a single amino acid substitution, deletion, modification and/or insertion.
  • the present invention provides a polynucleotide encoding the antibody or fragment of the first aspect of the invention.
  • the present invention provides a cell comprising the antibody or fragment thereof according to the first aspect of the invention and/or the polynucleotide of the second aspect of the invention.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the antibody according to the first aspect of the invention or the polynucleotide of the second aspect of the invention and further comprising one or more pharmaceutically acceptable diluents; carriers; excipients, fillers, binders, lubricants, glidants, disintegrants, adsorbents; and/or preservatives.
  • the present invention provides an antibody or antibody of the first aspect of the invention or a polynucleotide of the second aspect of the invention or a pharmaceutical composition of the fourth aspect of the invention for use in the treatment of HCV.
  • the terms used herein are defined as described in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", Leuenberger, H.G.W, Nagel, B. and Klbl, H. eds.
  • antibody or fragment thereof refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e. molecules that contain an antigen binding site that specifically binds an antigen. Also comprised are immunoglobulin-like proteins that are selected through techniques including, for example, phage display to specifically bind to a target molecule, e.g. to the target protein SR-B1.
  • the immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGl , IgG2, IgG3, IgG4, IgAl and IgA2) or subclass of immunoglobulin molecule.
  • Antibodies and fragments thereof suitable for use in the present invention include, but are not limited to, polyclonal, monoclonal, monovalent, bispecific, heteroconjugate, multispecific, human, humanized (in particular CDR-grafted), deimmunized, or chimeric antibodies, single chain antibodies (e.g.
  • scFv fragments
  • F(ab') 2 fragments fragments produced by a Fab expression library
  • diabodies or tetrabodies Holliger P. et al., 1993
  • nanobodies anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above.
  • the antibody fragments are mammalian, preferably human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab') 2 , Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (dsFv) and fragments comprising either a VL or VH domain.
  • Antigen-binding antibody fragments, including single-chain antibodies may comprise the variable domain(s) alone or in combination with the entirety or a portion of the following: hinge region, CL, CHI , CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable domain(s) with a hinge region, CL, CHI , CH2, and CH3 domains.
  • Antibodies usable in the invention may be from any animal origin including birds and mammals.
  • the antibodies are human, simian (e.g. chimpanzee, bonobo, macaque), rodent (e.g. mouse and rat), donkey, sheep rabbit, goat, guinea pig, camel, horse, or chicken. It is particularly preferred that the antibodies are of human or murine origin.
  • "human antibodies” include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described for example in U.S. Patent No. 5,939,598 by Kucherlapati & Jakobovits.
  • an antigen recognized by an antibody or fragment thereof of the invention is called an "epitope”.
  • SR-B1 and “SR-BI” are used interchangeably herein and refer to the
  • SR-BI Scavenger receptor class B, type I (SR-BI) which is an integral membrane protein found in numerous cell types, including liver and adrenal cells. This receptor mediates the uptake of cholesteryl esters from high-density lipoproteins in the liver.
  • An amino acid sequence of human SR-B1 receptor can be found e.g. under accession number: NP_005496.4 (NCBI sequence).
  • a first compound e.g. an antibody or antibody fragment
  • a second compound e.g. an antigen, such as a target protein
  • KD dissociation constant KD to said second compound of 100 ⁇ or less, preferably 50 ⁇ or less, preferably 30 ⁇ or less, preferably 20 ⁇ or less, preferably 10 ⁇ or less, preferably 5 ⁇ or less, more preferably 1 ⁇ or less, more preferably 900 nM or less, more preferably 800 nM or less, more preferably 700 nM or less, more preferably 600 nM or less, more preferably 500 nM or less, more preferably 400 nM or less, more preferably 300 nM or less, more preferably 200 nM or less, even more preferably 100 nM or less, even more preferably 90 nM or less, even more preferably 80 nM or less, even more preferably 70 nM or less, even more preferably 60 nM
  • a "patient” means any mammal or bird who may benefit from a treatment with the antibody of the invention or a fragment thereof. It is particularly preferred that the "patient” is a human being.
  • treat means accomplishing one or more of the following: (a) reducing the severity of the disorder; (b) limiting or preventing development of symptoms characteristic of the disorder(s) being treated; (c) inhibiting worsening of symptoms characteristic of the disorder(s) being treated; (d) limiting or preventing recurrence of the disorder(s) in patients that have previously had the disorder(s); and (e) limiting or preventing recurrence of symptoms in patients that were previously symptomatic for the disorder(s).
  • the terms “treat”, “treating” or “treatment” in all instances means that treatment occurs after the patient has contracted the disease.
  • administering includes in vivo administration, as well as administration directly to tissue ex vivo, such as vein grafts.
  • an “effective amount” is an amount of a therapeutic agent sufficient to achieve the intended purpose.
  • the effective amount of a given therapeutic agent will vary with factors such as the nature of the agent, the route of administration, the size and species of the animal to receive the therapeutic agent, and the purpose of the administration.
  • the effective amount in each individual case may be selected as described herein or determined empirically by a skilled artisan according to established methods in the art.
  • “Pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • the term "isolated” refers to a molecule which is substantially free of other molecules with which it is naturally associated with. An isolated molecule is thus free of other molecules that it would encounter or contact in a living animal in nature, i.e. outside an experimental setting.
  • the antibody or fragment thereof of the present invention is an isolated antibody or fragment thereof.
  • protein protein
  • peptide polypeptide
  • peptides peptides
  • polypeptides polypeptides
  • Peptides can be also chemically modified by modifying a side chain or a free amino or carboxy-terminus of a natural or non-naturally occurring amino acid. This chemical modification includes the addition of further chemical moieties as well as the modification of functional groups in side chains of the amino acids, such as a glycosylation.
  • a peptide is a polymer preferably having at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or at least 100 amino acids, most preferably at least 30 amino acids.
  • vector includes any vectors known to the skilled person including plasmid vectors, cosmid vectors, phage vectors such as lambda phage, filamentous phage vectors, viral vectors, adenovirus vectors, adeno-associated virus (AAV) vectors (e.g., AAV type 5 and type 2), alphavirus vectors (e.g., Venezuelan equine encephalitis virus (VEE), Sindbis virus (SIN), semliki forest virus (SFV), and VEE-SIN chimeras), herpes virus vectors, measles virus vectors, pox virus vectors (e.g., vaccinia virus, modified vaccinia virus Ankara (MVA), NYVAC (derived from the Copenhagen strain of vaccinia), and avipox vectors: canarypox (ALVAC) and fowlpox (FPV) vectors), and vesicular stomatitis virus vector
  • AAV adeno
  • CDR in the context of the antibody of the invention or fragment thereof, refers to any of the antibodies complementarity determining regions.
  • V domain of an antibody there are three CDRs (CDR1 , CDR2 and CDR3). Since antibodies are typically composed of two polypeptide chains, there is a frequency of about six CDRs for each antigen receptor that can come into contact with the antigen (each heavy and light chain contains three CDRs). Among these, CDR3 shows the greatest variability. CDR domains have been extensively studied and, thus, the average skilled person is well capable of identifying CDR regions, i.e. CDR1, CDR2 and CDR3 within a polypetide sequence of a VL and VH domain of an antigen receptor. In one preferred method, the CDR1, CDR2 and CDR3 regions of the VL domain are determined as follows:
  • the first amino acid of CDR1 is located at approx. residue 23 or 24 of the VL domain.
  • the residue before the first amino acid of the CDR1 is a conserved Cys residue.
  • the residues following the last amino acid of the CDR1 region is a conserved Trp residue followed typically by Tyr-Gln, but also, Leu-Gin, Phe-Gln or Tyr-Leu.
  • the length of the CDR1 of the VL domain is between 10 and 17 residues.
  • CDR2 is located 16 residues after the end of CDR1.
  • the residues before the first amino acid of CDR2 are generally Ile-Tyr, but also, Val-Tyr, Ile-Lys, Ile-Phe or similar.
  • the length of the CDR2 region is generally 7 residues.
  • CDR3 of the VL domain CDR3 region of the VL domain starts 33 residues after the end of the CDR2 region. The preceeding residue before the first amino acid of CDR3 is always Cys. CDR3 is followed by the amino acids Phe-Gly-XXX-Gly. The length of the CDR3 region is typically between 7 to 1 1 residues.
  • the CDRl, CDR2 and CDR3 regions of the VH domain are determined as follows:
  • the first amino acid of CDRl is located at approx. residue 26 of the VH domain (always 4 or 5 residues after a Cys).
  • the amino acid after the CDRl will be a Tip (Typically Trp-Val, but also, Trp-Ile or Tip- Ala).
  • the length of the CDRl of the VH domain is between 10 to 12 residues.
  • the CDR2 domain starts at residue 15 after the end of the CDRl of the VH domain.
  • the CDR2 domain is preceeded typically by the amino acids Leu-Glu-Trp-Ile-Gly or a variation thereof.
  • the CDR2 domain will be followed by the three amino acids (Lys/Arg)- (Leu/Ile/Val/Phe/Tl r/Ala)-(Thr/Ser/Ile/Ala) and comprises a total of about 16 to 19 residues.
  • the first amino acid of the CDR3 of the VH domain will be located 33 residues after the end of the CDR2 of the VH domain and will start always 3 amino acids after a conserved Cys residue (the preceding sequence is typically Cys-Ala-Arg).
  • CDR3 will be Trp-Gly-XXX-Gly.
  • the CDR3 of the VH domain will typically have a length of between 3 to 25 residues.
  • the inventors identified novel therapeutic antibodies with enhanced binding affinities to SR-B1.
  • the invention provides an antibody or fragment thereof, which specifically binds to the scavenger receptor class B type
  • SR-B1 scavenger receptor class B type 1
  • SR-B1 scavenger receptor class B type 1
  • the antibody or fragment thereof of the invention is capable of specifically binding to the same SR-B1 epitope that also an antibody is capable of specifically binding to which comprises a heavy chain with a VH domain and a light chain with a VL domain, wherein the VH and VL domains respectively have an amino acid sequence of any of i) through viii):
  • VH-domain SEQ ID NO
  • VL-domain SEQ ID NO: ii) 3 4;
  • the VH and VL chains of the novel antibodies of the invention comprise improved CDR1, CDR2 and CDR3 sequences with improved binding affinities to SR-Bl .
  • CDR3 shows not only the greatest variability but also the greatest contribution for specific binding.
  • the heavy chain of said antibody or fragment thereof comprises a CDR3 domain selected from a group of amino acid sequences consisting of SEQ ID NO: 13, 15, 17,
  • said CDR3 domain of the heavy chain may optionally comprise a single amino acid substitution, deletion, modification and/or insertion;
  • the light chain of said antibody or fragment thereof comprises a CDR3 domain selected from a group of amino acid sequences consisting of SEQ ID NO: 14, 16, 18,
  • said CDR3 domain of the light chain may optionally comprise a single amino acid substitution, deletion, modification and/or insertion.
  • Antibodies of the invention and fragment thereof can be modified to enhance stability and to enhance antigen binding.
  • Factors effecting stability include exposure of hydrophobic residues that are hidden at the interface of a whole Ig molecule at the constant domain interface; hydrophobic region exposure on the Fv surface leading to intermolecular interaction; and hydrophilic residues in the interior of the Fv beta sheet or at the normally interface between VH and VL.
  • Stability can be enhanced by substituting problematic residues impacting on stability. Such modifications can be achieved by e.g. effecting said single amino acid substitution, deletion, modification and/or insertion.
  • Techniques for enhancing single chain antibody stability taking into account problematic residue are well known in art. (Chowdhury et al., Engineering scFvs for Improved Stability, p. 237-254 in Recombinant Antibodies for Cancer Therapy Methods and Protocols, (Eds. Welschof and Krauss) Humana Press, Totowa, New Jersey, 2003.)
  • the antibody or fragment thereof of the invention comprises a pair of polypeptides that are selected from the group consisting of:
  • each polypeptide pair is respectively a CDR3 domain of the heavy chain and a CDR3 domain of the light chain of said antibody or fragment thereof; wherein each CDR3 domain optionally comprises one amino acid substitution, deletion or addition.
  • the heavy chain of said antibody or fragment thereof comprises a CDR3 domain having an amino acid sequence as specified in (iii);
  • the light chain of said antibody or fragment thereof comprises a CDR3 domain having an amino acid sequence as specified in (iii);
  • SEQ ID NO: 19 SEQ ID NO: 20;
  • the antibody or fragment thereof of the invention additionally comprises one or more of the following:
  • the heavy chain of said antibody or fragment thereof comprises a CDR1 domain selected from a group of amino acid sequences consisting of SEQ ID NO: 25, 27, 29, 31, 33, and 35; wherein said CDR1 domain of the heavy chain may optionally comprise a single amino acid substitution, deletion, modification and/or insertion;
  • the light chain of said antibody or fragment thereof comprises a CDR1 domain selected from a group of amino acid sequences consisting of SEQ ID NO: 26, 28, 30, 32, 34 and 36; wherein said CDR1 domain of the light chain may optionally comprise a single amino acid substitution, deletion, modification and/or insertion;
  • the heavy chain of said antibody or fragment thereof comprises a CDR2 domain selected from a group of amino acid sequences consisting of SEQ ID NO: 37, 39, 41 , 43, 45 and 47; wherein said CDR2 domain of the heavy chain may optionally comprise a single amino acid substitution, deletion, modification and/or insertion; and
  • the light chain of said antibody or fragment thereof comprises a CDR2 domain selected from a group of amino acid sequences consisting of SEQ ID NO: 38, 40, 42, 44, 46 and 48; wherein said CDR2 domain of the light chain may optionally comprise a single amino acid substitution, deletion, modification and/or insertion.
  • the VH domain of the heavy chain of said antibody or fragment thereof comprises the amino acid sequence selected from SEQ ID NO: 1 , 3, 5, 7, 9 and 1 1 ; wherein said VH domain may optionally comprise between 1 and 10, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 single amino acid substitutions, deletions, modifications and/or insertions, preferably each of the CDR1, CDR2 and CDR3 sequences do not exhibit more than one substitution, deletion, modification and/or insertion; and
  • the VL domain of the light chain of said antibody or fragment thereof comprises the amino acid sequence selected from SEQ ID NO: 2, 4, 6, 8, 10 and 12; wherein said VL domain may optionally comprise between 1 and 10, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or
  • each of the CDR1, CDR2 and CDR3 sequences do not exhibit more than one substitution, deletion, modification and/or insertion.
  • VH domain and VL domain are paired together 1 and 2; 3 and 4; 5 and 6; 7 and 8; 9 and 10; and 1 1 and 12 and together comprise between 0 and 15, more preferably between 0 and 10 i.e. 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 and most preferably between 0 and 3 single amino acid substitutions, deletions and insertions or amino acid substitutions, deletions or insertions, preferably substitutions, preferably with the proviso that not more than one or none of said substitutions, deletions, modifications and/or insertions are located within the CDR1 , CDR2 or CDR3 domains of the heavy chain or light chain.
  • the phrase "specifically binds” means that said antibody or fragment thereof binds to said SR-Bl receptor, preferably with a dissociation constant as defined herein above.
  • “specifically binds” means that said antibody or fragment thereof of the invention binds to said SR-B 1 receptor with a dissociation constant (Ko)of less than 10 nM as measured by binding titration on CHO cells expressing SR-B1 receptor.
  • Ko dissociation constant
  • Whole cell binding assays are well known in the art. For example, the average skilled person may determine said 3 ⁇ 4 to CHO cells that are stably transfected with human SR-B1 as follows:
  • PBS phosphate-buffered saline
  • BSA bovine serum albumin
  • FACS fluorescence-activated cell sorter
  • an antibody or fragment thereof interacts with an antigen such as with the SR-B 1 receptor.
  • assays as described in the examples below may be used.
  • the SR-B1 or a fragment thereof may be purified and immobilized on a solid phase such as beads.
  • the beads linked to SR-B1 may be contacted with the antibody or fragment thereof, washed and probed with a secondary antibody specific for an invariant part of the antibody or fragment thereof, available in the state of the art.
  • binding assays well known in the art and suitable to determine binding affinities between two binding partners can be used such as e.g. ELISA-based assays, fluorescence resonance energy transfer (FRET)-based assays, co-immunoprecipitation assays and plasmon-resonance assays.
  • the binding can be detected by fluorescence means, e.g. using a fluorescently labelled secondary antibody, or enzymatically as is well known in the art.
  • radioactive assays may be used to assess binding.
  • any of the aforementioned exemplary methods can be used to determine if an antibody or fragment thereof of the invention binds to SR-B1 and optionally also to determine with what dissociation constant KQ the antibody or fragment thereof binds the mentioned antigen.
  • the antibody or fragment thereof of the invention is capable of inhibiting transmission of HCV from an HCV infected mammalian cell to another cell, preferably to an non-infected cell contacting said infected cell.
  • the viral cell-to-cell transmission is inhibited to such degree that the HCV viral load of a subject can be reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even more compared to a control subject, which does not receive the antibody or fragment thereof of the invention.
  • the antibody of the invention is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a humanized antibody, a human antibody, a diabody, a tetrabody, a nanobody, a chimeric antibody, and a deimmunized antibody.
  • the fragment of the antibody of the invention is an antibody fragment selected from the group consisting of Fab, F(ab') 2 , Fd, Fv, single-chain Fv, and disulfide-linked Fvs (dsFv).
  • the invention provides a polynucleotide encoding the VH and/or VL domain of the antibody or fragment thereof according to the invention.
  • the polynucleotide of the invention may be a composition comprising a first and a second polynucleotide, wherein the first polynucleotide comprises or consists of a polynucleotide that encodes a VL region according to any of SEQ ID NO: 2, 4, 6, 8, 10 and 12 optionally comprising not more than two, preferably a single amino acid substitution, deletion, modification and/or insertion and the second polynucleotide comprises or consists of a polynucleotide encoding a VH region according to any of SEQ ID NO: 1 , 3, 5, 7, 9 and 1 1 optionally comprising not more than two, preferably a single amino acid substitution, deletion, modification and/or insertion.
  • the polynucleotide of the invention is comprised in a vector as defined herein.
  • An antibody of the invention or a fragment thereof can be generated e.g. by recombinant expression of a polynucleotide of the invention or by or through the use of a hybridoma.
  • a hybridoma is an immortalized cell line producing the antigen binding protein.
  • a hybridoma is an immortalized antibody producing cell line.
  • a hybridoma can be produced using techniques such as those described in Ausubel Current Protocols in Molecular Biology, John Wiley, 1987-1998, Harlow et al., Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, 1988, and Kohler et al, Nature 256, 495-497, 1975.
  • the polynucleotide of the invention can be expressed in a host cell, preferably a human cell.
  • the expression can be carried out by using a vector comprising a polynucleotide of the invention.
  • the vector is an expression vector or viral, e.g. adenoviral vector.
  • the viral vector is preferably capable of expressing the polynucleotide of the invention in a target cell and thus useful for transgenic expression of antibodies of the invention and/or fragments thereof in such target cell which is preferably a human cell.
  • the expression vector may further comprise regulatory elements for protein expression.
  • the regulatory elements that can be used include a transcriptional promoter, a ribosome binding site, a terminator, and an operator.
  • a preferred element for processing in eukaryotic cells is a polyadenylation signal.
  • Antibody associated introns may also be present. Examples of expression cassettes for antibody or antibody fragment production are well known in art. (E.g., Persic et al. Gene 187:9-18, 1997, Boel et al, J. Immunol. Methods 239: 153-166, 2000, Liang et al, J. Immunol. Methods 247: 119-130, 2001.)
  • the vector may further comprise also an origin of replication for autonomous replication in a host cell, a selectable marker, a limited number of useful restriction enzyme sites, and a potential for high copy number.
  • a variety of different cell lines can be used for recombinant antigen binding protein expression, including those from prokaryotic organisms (e.g., E. coli, Bacillus, and Streptomyces) and from Eukaryotic organisms (e.g., yeast, insect and mammalian). (Breitling et al., Recombinant Antibodies, John Wiley & Sons, Inc.
  • Preferred hosts for recombinant expression of the antibody of the invention or a fragment thereof are mammalian cells able to produce antigen binding protein with proper post translational modifications.
  • Post translational modifications include disulfide bond formation and glycosylation.
  • Another type of post translational modification is signal peptide cleavage. Proper glycosylation can be important for antibody function.
  • Naturally occurring antibodies typically contain at least one N-linked carbohydrate attached to a heavy chain.
  • Additional N-linked carbohydrates and O-linked carbohydrates may be present and may be important for antibody function.
  • mammalian host cells can be used to provide for efficient post- translational modifications.
  • Examples of such host cells include Chinese hamster ovary (CHO), HeLa, C6, PC 12, and myeloma cells (see e.g. Yoo et al, Journal of Immunological Methods 267: 1-20, 2002, Persic et al, Gene 787:9-18, 1997).
  • variable regions and/or complementary determining regions from the heavy and light chains can be used and incorporated into said single chain antibody.
  • Techniques for incorporating a variable region into an antibody or an antibody fragment are well known in the art. (E.g., Azzazy et al., Clinical Biochemistry 35:425-445, 2002, Persic et al., Gene 757:9-18, 1997.) In one example the average skilled person can follow the technique as described in the following:
  • the Fv domains are separately amplified using PCR primers specific for the VH and VL regions, the primers can include additional nucleotides for introducing unique restriction sites, for providing splice sites, and encoding additional amino acids.
  • the amplified variable encoding regions are incorporated into mammalian expression cassettes.
  • VH encoding nucleic acid can be inserted into a plasmid containing a cassette for expressing a human heavy (e.g., human gamma 4 heavy chain), while the VL encoding region can be introduced into a vector expressing a light chain (e.g., human lambda light chain). Both vectors should carry an intron between the leader sequence and the constant region sequence of the antibody.
  • the intron should contain unique restriction sites suitable for cloning the amplified Fy domains.
  • IgG production is achieved by co-transfecting the VH and VL expression vector in 293-EBNA cells.
  • Numerous variations of the outlined procedure can be performed to incorporate a variable region into an antibody or an antibody fragment. Such variations include, for example, using a vector encoding different types of antibody light and heavy chains or fragments thereof, using a single vector, and using different types of host cells.
  • the invention provides a cell comprising the antibody or fragment thereof according to the invention and/or the polynucleotide according to the invention.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the antibody or fragment thereof according to the invention and/or the a polynucleotide of the invention and further comprising one or more pharmaceutically acceptable diluents; carriers; excipients, fillers, binders, lubricants, glidants, disintegrants, adsorbents; adjuvants and/or preservatives.
  • the pharmaceutical composition of the invention can be used in the form of systemically administered medicaments.
  • parenterals which comprise among others injectables and infusions.
  • injectables are formulated either in the form of ampoules or as so called ready-for-use injectables, e.g. ready-to-use syringes or single-use syringes and aside from this in puncturable flasks for multiple withdrawal.
  • the administration of injectables can be in the form of subcutaneous (s.c), intramuscular (i.m.), intravenous (i.v.) or intracutaneous (i.e.) application.
  • Injectable formulations can further be produced as concentrates, which can be dissolved or dispersed with aqueous isotonic diluents.
  • the infusion can also be prepared in form of isotonic solutions, fatty emulsions, liposomal formulations and micro-emulsions. Similar to injectables, infusion formulations can also be prepared in the form of concentrates for dilution. Injectable formulations can also be applied in the form of permanent infusions both in in-patient and ambulant therapy, e.g. by way of mini-pumps.
  • parenteral drug formulations for example, albumin, plasma, expander, surface-active substances, organic diluents, pH-influencing substances, complexing substances or polymeric substances, in particular as substances to influence the adsorption of the pharmaceutical composition of the invention to proteins or polymers or they can also be added with the aim to reduce the adsorption of the pharmaceutical composition of the invention to materials like injection instruments or packaging-materials, for example, plastic or glass.
  • the pharmaceutical composition of the invention can in some embodiments also be bound to microcarriers or nanoparticles in parenterals like, for example, to finely dispersed particles based on poly(meth)acrylates, polylactates, polyglycolates, polyamino acids or polyether urethanes.
  • the pharmaceutical composition of the invention can also be modified as depot preparations, e.g. based on the "multiple unit principle", if the composition of the invention is introduced in finely dispersed, dispersed and suspended form, respectively, or as a suspension of crystals in the medicament or based on the "single unit principle” if the composition of the invention is enclosed in a formulation, e.g. in a tablet or a rod which is subsequently implanted.
  • implants or depot medicaments in single unit and multiple unit formulations often consist out of so called biodegradable polymers like e.g. polyesters of lactic and glycolic acid, polyether urethanes, polyamino acids, poly(meth)acrylates or polysaccharides.
  • biodegradable polymers like e.g. polyesters of lactic and glycolic acid, polyether urethanes, polyamino acids, poly(meth)acrylates or polysaccharides.
  • Adjuvants in a composition of the invention may preferably be aqua sterilisata (sterilized water), pH value influencing substances like, e.g. organic or inorganic acids or bases as well as salts thereof, buffering substances for adjusting pH values, substances for isotonization like e.g. sodium chloride, sodium hydrogen carbonate, glucose and fructose, tensides and surfactants, respectively, and emulsifiers like, e.g. partial esters of fatty acids of polyoxyethylene sorbitans (for example, Tween ® ) or, e.g. fatty acid esters of polyoxyethylenes (for example, Cremophor ® ), fatty oils like, e.g.
  • pH value influencing substances like, e.g. organic or inorganic acids or bases as well as salts thereof
  • buffering substances for adjusting pH values e.g. sodium chloride, sodium hydrogen carbonate, glucose and fructose, tensides and surfactants, respectively
  • peanut oil, soybean oil or castor oil synthetic esters of fatty acids like, e.g. ethyl oleate, isopropyl myristate and neutral oil (for example, Miglyol ® ) as well as polymeric adjuvants like, e.g. gelatine, dextran, polyvinylpyrrolidone, additives which increase the solubility of organic solvents like, e.g. propylene glycol, ethanol, N,N-dimethylacetamide, propylene glycol or complex forming substances like, e.g. citrate and urea, preservatives like, e.g. benzoic acid hydroxypropyl ester and methyl ester, benzyl alcohol, antioxidants like e.g. sodium sulfite and stabilizers like e.g. EDTA.
  • synthetic esters of fatty acids like, e.g. ethyl oleate, isopropyl myristate and neutral
  • thickening agents to prevent the setting of the pharmaceutical composition of the invention or, tensides and polyelectrolytes to assure the resuspendability of sediments and/or complex forming agents like, for example, EDTA are added.
  • tensides and polyelectrolytes to assure the resuspendability of sediments and/or complex forming agents like, for example, EDTA are added.
  • complexes of the active ingredient with various polymers. Examples of such polymers are polyethylene glycol, polystyrol, carboxymethyl cellulose, Pluronics ® or polyethylene glycol sorbit fatty acid ester.
  • dispersing agents can be added as further adjuvants.
  • scaffolding agents like mannite, dextran, saccharose, human albumin, lactose, PVP or varieties of gelatine can be used.
  • the invention also provides the antibody according to the invention or the pharmaceutical composition according to the invention for treating or preventing a HCV infection, preferably a chronic HCV infection.
  • chronic HCV infection is preferably defined as the persistence of HCV RNA in the blood for one month or more, preferably of two months or more or most preferably for six months or more.
  • the immune system has failed to clear the virus from the body. Therefore, individuals with chronic hepatitis C will persistently have an elevated HCV RNA.
  • Once a person is chronically infected with HCV the potential exists for liver damage and cirrhosis along with its complications, including liver failure and liver cancer. Approximately 60-85 percent of HCV infected people develop chronic hepatitis C.
  • the invention relates to anti-SR-Bl antibodies, which specifically bind to the scavenger receptor class B type 1 for the treatment of chronic HCV.
  • an alternative way of administering an antibody is the administration of a nucleic acid encoding the antibody, which is then expressed in the patient.
  • Expression can be achieved by numerous technologies known in the art comprising transfection of mRNA or transfection or infection of encoding nucleotides in vectors, which include viral vectors and plasmid vectors.
  • the invention also relates to a nucleic acids encoding the antibody of the invention for the treatment or prophylaxis of HCV infection, in particular for the treatment of chronic HCV infection.
  • antibodies of the present invention when used at a concentration of 0.008 ⁇ g/ml, is capable of reducing an HCV infection by more than 50% (cf. Figure 5).
  • the antibodies of the invention are capable of reducing HCV infection when used at a concentration of 0,008 ⁇ g/ml, by more than 50% compared to an HCV infection that is observed, when no antibodies are used.
  • said reduction in infection is determined using RT-PCR, for example as outlined in example 4 below.
  • An average skilled person can determine the reduction of infection of HCV by e.g. using the neutralization/blocking assay set forth in the examples below.
  • a single amino acid substitution, deletion, modification and/or insertion of a protein or polypeptide generally refers to a modified version of the recited protein or polypeptide, e.g. one amino acid of the protein or polypeptide may be deleted, inserted, modified and/or substituted. If the polypeptide or protein comprises several single amino acid substitutions, deletions, modifications and/or insertions then the total number of such substitutions, deletions, modifications and/or insertions is indicated in each case. Said insertion is an insertion of the indicated number of single amino acids into the original polypeptide or protein. An amino acid of the protein or polypeptide may also be modified, e.g. chemically modified by the total number of modifications indicated.
  • the side chain or a free amino or carboxy-terminus of an amino acid of the protein or polypeptide may be modified by e.g. glycosylation, amidation, phosphorylation, ubiquitination, e.t.c.
  • the chemical modification can also take place in vivo, e.g. in a host-cell, as is well known in the art.
  • a suitable chemical modification motif e.g. glycosylation sequence motif present in the amino acid sequence of the protein will cause the protein to be glycosylated.
  • the polypeptide or protein comprises one or more single amino acid substitutions, said substitutions may in each case independently be a conservative or a non-conservative substitution, preferably a conservative substitution.
  • substitutions are of conservative nature as further defined below.
  • a substitution also includes the exchange of a naturally occurring amino acid with a not naturally occurring amino acid.
  • a conservative substitution comprises the substitution of an amino acid with another amino acid having a chemical property similar to the amino acid that is substituted.
  • the conservative substitution is a substitution selected from the group consisting of:
  • a basic amino acid is preferably selected from the group consisting of arginine, histidine, and lysine.
  • An acidic amino acid is preferably aspartate or glutamate.
  • An aromatic amino acid is preferably selected from the group consisting of phenylalanine, tyrosine and tryptophane.
  • a non-polar, aliphatic amino acid is preferably selected from the group consisting of glycine, alanine, valine, leucine, methionine and isoleucine.
  • a polar, uncharged amino acid is preferably selected from the group consisting of serine, threonine, cysteine, proline, asparagine and glutamine.
  • a non-conservative amino acid substitution is the exchange of one amino acid with any amino acid that does not fall under the above-outlined conservative substitutions (i) through (v).
  • a protein or polypeptide comprises one or an indicated number of single amino acid deletions, then said amino acid(s) present in the reference polypeptide or protein sequence have been removed.
  • the pharmaceutical composition of the invention can be administered by various well known routes, including oral, rectal, intragastrical and parenteral administration (see also above), e.g. intravenous, intramuscular, intranasal, intradermal, subcutaneous and similar administration routes. Parenteral-, intramuscular- and intravenous administration is preferred.
  • the pharmaceutical according to the invention is formulated as syrup, an infusion or injection solution, a tablet, a capsule, a capslet, lozenge, a liposome, a suppository, a plaster, a band-aid, a retard capsule, a powder, or a slow release formulation.
  • the diluent is water, a buffer, a buffered salt solution or a salt solution and the carrier preferably is selected from the group consisting of cocoa butter and vitebesole.
  • Particular preferred pharmaceutical forms for the administration of the pharmaceutical according to the invention during the use of the present invention are forms suitable for injectable use and include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • a solution or dispersion will include a solvent or dispersion medium, containing, for example, water-buffered aqueous solutions, e.g. biocompatible buffers, ethanol, polyol, such as glycerol, propylene glycol, polyethylene glycol, suitable mixtures thereof, surfactants or vegetable oils.
  • Infusion or injection solutions can be accomplished by any number of art recognized techniques including but not limited to addition of preservatives like anti-bacterial or anti- fungal agents, e.g. parabene, chlorobutanol, phenol, sorbic acid or thimersal. Further, isotonic agents, such as sugars or salts, in particular sodium chloride may be incorporated in infusion or injection solutions.
  • preservatives like anti-bacterial or anti- fungal agents, e.g. parabene, chlorobutanol, phenol, sorbic acid or thimersal.
  • isotonic agents such as sugars or salts, in particular sodium chloride may be incorporated in infusion or injection solutions.
  • Preferred diluents of the present invention are water, physiological acceptable buffers, physiological acceptable buffer salt solutions or salt solutions.
  • Preferred carriers are cocoa butter and vitebesole. Excipients which can be used with the various pharmaceutical forms of the pharmaceutical according to the invention can be chosen from the following non-limiting list:
  • binders such as lactose, mannitol, crystalline sorbitol, dibasic phosphates, calcium phosphates, sugars, microcrystalline cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, polyvinyl pyrrolidone and the like;
  • lubricants such as magnesium stearate, talc, calcium stearate, zinc stearate, stearic acid, hydrogenated vegetable oil, leucine, glycerids and sodium stearyl fumarates,
  • disintegrants such as starches, croscaramellose, sodium methyl cellulose, agar, bentonite, alginic acid, carboxymethyl cellulose, polyvinyl pyrrolidone and the like.
  • compositions according to the invention are preferred for the therapy of a disease. It is, however, understood that depending on the severity of the disease, the type of the disease, as well as on the respective patient to be treated, e.g. the general health status of the patient, etc., different doses of the pharmaceutical composition according to the invention are required to elicit a therapeutic effect. The determination of the appropriate dose lies within the discretion of the attending physician.
  • the antibodies, nucleic acids encoding such antibodies or the pharmaceutical compositions of the invention can be used in method of treating or preventing HCV infection, preferably of chronic HCV infection.
  • Fig. 1 CDR regions of anti-SR-Bl monoclonal antibodies - VH regions.
  • the alignment illustrates the different VH regions of the monoclonal antibodies mAb 8 (SEQ ID NO: 1), mAb 8-1 (SEQ ID NO: 3), mAb 15 (SEQ ID NO: 5), mAb 15-1 (SEQ ID NO: 7), mAb 15-2 (SEQ ID NO: 9) and mAb 6 (SEQ ID NO: 1 1).
  • Fig. 2 CDR regions of anti-SR-Bl monoclonal antibodies - VL regions.
  • the alignment illustrates the different VL regions of the monoclonal antibodies mAb 8 (SEQ ID NO: 2), mAb 8-1 (SEQ ID NO: 4), mAb 15 (SEQ ID NO: 6), mAb 15-1 (SEQ ID NO: 8), mAb 15-2 (SEQ ID NO: 10) and mAb 6 (SEQ ID NO: 12).
  • Fig. 4 HCVcc infection inhibited by anti-SRBl mAb measured by q-PCR.
  • Huh7 cells were infected with HCVcc (J6/JFH1) after pre-incubation with anti-SR-Bl mAbs at a concentration of 10 ⁇ . Infectivity was measured by RT PCR assay 3 days postinfection. On the vertical axis it is shown the percentage of HCVcc infection in the presence of mAbs, relative to that measured in the absence of anti-SRB 1 mAb.
  • Fig. 5 Neutralization of J6/JFH1 HCVcc infection by anti-SR-Bl mAbs.
  • Huh7.5 cells were infected with HCVcc upon pre-incubation with increasing concentrations (ng/ml) of anti-SR-Bl mAbs (indicated on the horizontal axis on a logarithmic scale). Infectivity was measured 3 days post-infection. On the vertical axis is shown the percentage of HCV (% infection) measured in cells infected in the presence of mAbs, relative to the number of HCV copies measured in no-antibody-treated cells. Neutralization curves were extrapolated by fitting experimental data with the Sigma Plot program.
  • Fig. 6 Efficacy of mAb8 in prevention mode: mAb8 can prevent HCV infection in vivo.
  • Fig. 7 Efficacy of mAb8 in post-exposure therapeutic mode: mAb8 reduces HCV post exposure in vivo.
  • Fig. 8 Apparent affinity of anti-SRBl mAbs.
  • Huh-7.5/shSR- Bl/KRAB cells are stable derivatives of the human hepatoma Huh-7.5 cell line, where endogenous SR-BI expression can be reversibly downregulated by a stably transfected doxycycline inducible SR-BI-specific short hairpin RNA (shRNA) sequence (Catanese M.T. et al. 2010, Role of SR-BI in HCV entry: kinetics and molecular determinants. J Virol. 84(l):34-43).
  • shRNA short hairpin RNA
  • Huh-7.5/shSR-Bl/KRAB cells pre-treated or not with lOOng/ml doxycycline (DOX) for 6 days, were infected with HCVcc in the presence or absence of DOX.
  • Cell monolayers grown on polylysine-coated wells were fixed, permeabilized and stained with an anti HCV core antibody conjugated to HRP at 3 days post HCV infection ( Figure 3, Exp n.l) or with an anti HCV NS5a antibody conjugated to HRP at 2 days post HCV infection ( Figure 3, Exp n.2).
  • downregulation of SR-Bl reduces the number of cell foci that are positive for HCV infection (+DOX). Images representative of the wells are shown in Figure 3.
  • scFv were selected from single-chain Fv (scFv) libraries.
  • the library provides single-chain antibody fragments containing a variable domain of heavy chain and light chain exposed on the surface of a filamentous phage as a fusion to the coat protein pill.
  • E. Coli TGI cells New England Biolabs, Beverly, MA were infected with eluted phage and plated on 2X TY agar containing 2% glucose and 100 mg/mL ampicillin (2X TYAG).
  • Phage rescue and amplification was carried out as described (Hegmans JP, Radosevic K, Voerman JS, Burgers JA, Hoogsteden HC, et al. (2002) A model system for optimising the selection of membrane antigen-specific human antibodies on intact cells using phage antibody display technology. J Immunol Methods 262: 191-204).
  • the selected phage were panned again on the same cell line.
  • a variable number of clones (in the range 100-1 ,000) were randomly chosen from the pool of selected phage and tested by phage ELISA for their ability to bind HuH7 cells by whole-cell phage-ELISA.
  • mAbs 8, 81 , 15, 151 , 152 and 6 were generated by subcloning the variable regions from the different phages specifically binding CHO/SR-B1 into two eukaryotic vectors for the expression of heavy (immunoglobulin G4 [IgG4] isotype) and light chains, as previously described (Persic, L., A. Roberts, J. Wilton, A. Cattaneo, A. Bradbury, and H. R. Hoogenboom. 1997. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 10:9-18.).
  • HEK-293 EBNA cells were cotransfected into HEK-293 EBNA cells with Lipofectamine (Invitrogen), and whole human IgG4 was purified from culture medium with Hi-Trap protein A columns (Amersham Biosciences).
  • HEK-293 EBNA cells were grown in DMEM with 10% FBS, 1% nonessential amino acids, and G418 at 0.25 mg/ml.
  • Example 4 mAb 6, 8, 81, 15, 151 and 152 are capable of preventing HCVcc infection in vitro of human hepatoma cells HuH7.5
  • HCVcc virus generated from plasmids carrying HCV (J6/JFH1 -genotype 2a) genomic cDNA.
  • Huh 7.5 cells were seeded in 24-well plates (2.5 x 10 4 cells/well) in DEMEM-10% FBS.
  • the cells were preincubated for lh with 250 ⁇ ih of medium with increasing concentrations of antibodies.
  • HCVcc containing supernatant was added at a Multiplicity of Infection (m.o.i.) of 0.1 and the mixture was incubated for 3h.
  • the virus was removed and the medium was replaced with fresh medium containing the mAb at the same concentration used in the pre-incubation.
  • the infection was allowed to proceed for 3 days.
  • RNA was extracted and quantified (RNeasy mini kit from Qiagen).
  • the TaqMan was performed in 98-well plate using 50 ng of total RNA.
  • the total volume of each sample was 25 ⁇ L (One-Step RT-PCR Master mix Reagent - Applied Biosystems).
  • the primers and probe used in experiments were:
  • mAbs 6, 8, 15, 151 and 152 are able to reduce infection of HuH7.5 cell by HCVcc.
  • a dose response of the inhibitory activity of mAbs 6, 8, 81, 15, 151 and 152 was performed to calculate the activity of the antibodies (EC50). The experiment was performed as described above.
  • Figure 5 shows the inhibitory curves of mAbs 6, 8 and 151.
  • table 1 are reported the inhibitory activities of all six mAbs.
  • Example 5 mAb8 inhibits infection of HCV in AlbUPA-SCID chimeric mice uPA-SCID mice were transplanted with cryopreserved primary human hepatocytes (BD Biosciences). HCV RNA in mouse plasma was quantified using a commercial real-time PCR (Roche TaqMan48). Depending on the dilution of the plasma, the detection limit of this assay ranged from 375 IU/ml to 1.500 IU/ml.
  • HCV infection was measured by quantitative PCR on total RNA extracted from blood. Values below the limit of detection (LOD) were arbitrarily set at 375 IU/ml. As shown in Figure 6 mAb8 prevents HCV infection in vivo. Thus, antibodies against SRB1 can prevent infection of HCV virus.
  • Example 6 mAb8 prevent virus spread and amplification when they are administered after challenge
  • mice Chimeric mice were injected with 10 4 or 10 5 IU of H77 virus on day 0. Three days later, plasma was harvested and HCV RNA was quantified. HCV-positive animals were divided in different groups to receive 5 doses of 400 ⁇ g of mAb8 (days 3, 5, 7, 10 and 12), or no antibody as a control. All animals were bled on a weekly basis and the evolution of HCV RNA was monitored via RT-qPCR. As shown in Figure 7, all control animals experienced a rapid increase in viral load during the first two weeks after inoculation.
  • HCV RNA remained detectable in mAb8 treated animals but was several logs below the level of untreated animals and, in some cases, below the linear range of the RT-PCR test (+, ⁇ 375 IU/ml) and was therefore not quantifiable. 1 out of 2 animals in the mAb8 treated group remained at the limit of detection of the RT-qPCR test until the end of the observation (day 21). Thus, as shown in Figure 7 mAb8 inhibits virus spread and amplification in vivo when it is administered after HCV infection.
  • Example 7 Determination of apparent affinities of mAb6, 8, 15 and 151
  • the apparent affinity of the antibodies was determined as follows. Human hepatoma HepG2 cells were grown in Dulbecco's modified essential medium (DMEM; Invitrogen) supplemented with 10% FBS. 7.5 x 10 5 cells were incubated for 3 hours at room temperature with different amounts of anti-SR-Bl mAbs in phosphate-buffered saline (PBS)-0.2% bovine serum albumin (BSA)-HEPES at 10 mM (fluorescence-activated cell sorter [FACS] buffer). anti-SR-Bl MAbs binding was revealed by Fc (gamma) fragment specific, allophycocyanin- conjugated goat anti-human IgG. As a control, isotype-matched human IgG4 was used. FACS acquisitions and analysis were performed with a FACScalibur (Becton Dickinson) and CellQuest software.
  • DMEM Dulbecco's modified essential medium
  • FBSA bovine serum albumin
  • FACS flu

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps spécifiques du récepteur éboueur (« scavenger ») de classe B de type 1 (SR-B1) et l'utilisation des anticorps spécifiques du SR-B1 dans le traitement du VHC.
PCT/EP2011/000157 2010-01-15 2011-01-14 Anticorps pour le traitement du vhc WO2011086001A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29561810P 2010-01-15 2010-01-15
US61/295,618 2010-01-15

Publications (1)

Publication Number Publication Date
WO2011086001A1 true WO2011086001A1 (fr) 2011-07-21

Family

ID=43733969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/000157 WO2011086001A1 (fr) 2010-01-15 2011-01-14 Anticorps pour le traitement du vhc

Country Status (1)

Country Link
WO (1) WO2011086001A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016084062A1 (fr) * 2014-11-25 2016-06-02 Rappaport Family Institute For Research In The Medical Sciences Nouvel épitope en tant que cible pour la thérapie de maladies inflammatoires auto-immunes et du rejet de greffe
WO2020160560A3 (fr) * 2019-02-01 2020-09-17 Novarock Biotherapeutics, Ltd. Anticorps anti-claudine 18 et leurs méthodes d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017516A1 (fr) 1993-12-23 1995-06-29 Merck & Co., Inc. Systeme d'expression d'anticorps par recombinaison homologue s'appliquant a des cellules murines
US5939598A (en) 1990-01-12 1999-08-17 Abgenix, Inc. Method of making transgenic mice lacking endogenous heavy chains
WO2006005465A1 (fr) * 2004-07-08 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Proteine de liaison a des antigenes dirigees contre le recepteur capteur b1, lesquelles inhibent la replication du vhc

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939598A (en) 1990-01-12 1999-08-17 Abgenix, Inc. Method of making transgenic mice lacking endogenous heavy chains
WO1995017516A1 (fr) 1993-12-23 1995-06-29 Merck & Co., Inc. Systeme d'expression d'anticorps par recombinaison homologue s'appliquant a des cellules murines
WO2006005465A1 (fr) * 2004-07-08 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Proteine de liaison a des antigenes dirigees contre le recepteur capteur b1, lesquelles inhibent la replication du vhc

Non-Patent Citations (41)

* Cited by examiner, † Cited by third party
Title
"Ausubel Current Protocols in Molecular Biology", 1987, JOHN WILEY
"Helvetica Chimica Acta, CH-4010 Basel, Switzerland", 1995, article "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)"
"Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals", 1996, CRC PRESS
"United States Pharmacopeia-25/National Formulary-20", 2001, UNITED STATES PHARMCOPEIAL CONVENTION, INC.
ACTON, S. ET AL.: "Identification of scavenger receptor SR-B as a high density lipoprotein receptor", SCIENCE, vol. 271, 1996, pages 518 - 20, XP002095410, DOI: doi:10.1126/science.271.5248.518
AGNELLO, V. ET AL.: "Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor", PROC NATL ACAD SCI U S A, vol. 96, 1999, pages 12766 - 71, XP002174322, DOI: doi:10.1073/pnas.96.22.12766
AUSUBEL: "Current Protocols in Molecular Biology", 1987, JOHN WILEY
AXEL KLEEMANN; JURGEN ENGEL: "Pharmaceutical Substances: Syntheses, Patents, Applications", 1999, THIEME MEDICAL PUBLISHING
AZZAZY ET AL., CLINICAL BIOCHEMISTRY, vol. 35, 2002, pages 425 - 445
BARTH, H. ET AL.: "Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulphate", J BIOL CHEM, vol. 278, 2003, pages 41003 - 12, XP002666885, DOI: doi:10.1074/JBC.M302267200
BOEL ET AL., J. IMMUNOL. METHODS, vol. 239, 2000, pages 153 - 166
BREITLING ET AL.: "Recombinant Antibodies", 1999, JOHN WILEY & SONS, INC. AND SPEKTRUM AKADEMISCHER VERLAG
CALVO, D.; M. A. VEGA: "Identification, primary structure, and distribution of CLA-1, a novel member of the CD36/LIMPII gene family", J BIOL. CHEM., vol. 268, 1993, pages 18929 - 35, XP002073610
CATANESE M.T. ET AL.: "Role of SR-BI in HCV entry: kinetics and molecular determinants", J VIROL., vol. 84, no. 1, 2010, pages 34 - 43
CATANESE MARIA TERESA ET AL: "High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein", JOURNAL OF VIROLOGY, vol. 81, no. 15, August 2007 (2007-08-01), pages 8063 - 8071, XP002629861, ISSN: 0022-538X *
CHOWDHURY ET AL.: "Engineering scFvs for Improved Stability", 2003, HUMANA PRESS, article "Recombinant Antibodies for Cancer Therapy Methods and Protocols", pages: 237 - 254
EVANS, M. J. ET AL.: "Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry", NATURE, vol. 446, 2007, pages 801 - 5, XP002516759, DOI: doi:10.1038/NATURE05654
HARLOW ET AL.: "Antibodies, A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
HEGMANS JP; RADOSEVIC K; VOERMAN JS; BURGERS JA; HOOGSTEDEN HC ET AL.: "A model system for optimising the selection of membrane antigen-specific human antibodies on intact cells using phage antibody display technology", J IMMUNOL METHODS, vol. 262, 2002, pages 191 - 204, XP004352189, DOI: doi:10.1016/S0022-1759(02)00005-4
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497
LIANG ET AL., J. IMMUNOL METHODS, vol. 247, 2001, pages 119 - 130
LIANG ET AL., J. IMMUNOL. METHODS, vol. 247, 2001, pages 119 - 130
MEULEMAN P. ET AL.: "Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo", HEPATOLOGY, vol. 48, no. 6, December 2008 (2008-12-01), pages 1761 - 1768, XP002610195, DOI: doi:10.1002/HEP.22547
MEULEMAN P; HESSELGESSER J; PAULSON M; VANWOLLEGHEM T; DESOMBERE I; REISER H; LEROUX-ROELS G: "Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo", HEPATOLOGY, vol. 48, no. 6, December 2008 (2008-12-01), pages 1761 - 8, XP002610195, DOI: doi:10.1002/HEP.22547
MEULEMAN PHILIP ET AL: "Anti-CD81 Antibodies Can Prevent a Hepatitis C Virus Infection In Vivo", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 48, no. 6, 1 December 2008 (2008-12-01), pages 1761 - 1768, XP002610195, ISSN: 0270-9139, DOI: DOI:10.1002/HEP.22547 *
O'BRIEN: "Humanization of Monoclonal Antibodies", vol. 207, 2003, HUMANA PRESS, article "From Methods in Molecular Biology VoI 207: Recombinant antibodies for Cancer Therapy: Methods and Protocols", pages: 81 - 100
PERSIC ET AL., GENE, vol. 187, 1997, pages 9 - 18
PERSIC ET AL., GENE, vol. 757, 1997, pages 9 - 18
PERSIC ET AL., GENE, vol. 787, 1997, pages 9 - 18
PERSIC, L.; A. ROBERTS; J. WILTON; A. CATTANEO; A. BRADBURY; H. R. HOOGENBOOM: "An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries", GENE, vol. 10, 1997, pages 9 - 18, XP002057893, DOI: doi:10.1016/S0378-1119(96)00628-2
PILERI, P. ET AL.: "Binding of hepatitis C virus to CD81", SCIENCE, vol. 282, 1998, pages 938 - 41, XP002092549, DOI: doi:10.1126/science.282.5390.938
PLOSS ET AL.: "Human occludin is a hepatitis C virus entry factor required for infection of mouse cells", NATURE, vol. 457, no. 7231, 12 February 2009 (2009-02-12), pages 882 - 6, XP002669214, DOI: doi:10.1038/NATURE07684
RHAINDS, D.; L. BRISSETTE: "The role of scavenger receptor class B type 1 (SR-Bl) in lipid trafficking, defining the rules for lipid traders", INT. J. BIOCHEM. CELL. BIOL., vol. 36, 2004, pages 39 - 77
SCARSELLI, E. ET AL.: "The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus", EMBO J., vol. 21, 2002, pages 5017 - 5025, XP002243428, DOI: doi:10.1093/emboj/cdf529
SHEPARD, C. W.; L. FINELLI; M. J. ALTER.: "Global epidemiology of hepatitis C virus infection", LANCET INFECT DIS, vol. 5, 2005, pages 558 - 67, XP005040965, DOI: doi:10.1016/S1473-3099(05)70216-4
SILVER, D. ET AL.: "High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion", J. BIOL. CHEM., vol. 276, 2001, pages 25287 - 93
VOISSET C. ET AL., J. BIOL. CHEM., vol. 280, 2005, pages 7793 - 7799
WASLEY, A.; M. J. ALTER: "Epidemiology of hepatitis C: geographic differences and temporal trends", SEMIN LIVER DIS, vol. 20, 2000, pages 1 - 16
YOO ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 261, 2002, pages 1 - 20
YOO ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 267, 2002, pages 1 - 20
ZHANG, J. ET AL.: "CD81 is required for hepatitis C virus glycoprotein-mediated viral infection", J VIROL, vol. 78, 2004, pages 1448 - 55, XP055045828, DOI: doi:10.1128/JVI.78.3.1448-1455.2004

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016084062A1 (fr) * 2014-11-25 2016-06-02 Rappaport Family Institute For Research In The Medical Sciences Nouvel épitope en tant que cible pour la thérapie de maladies inflammatoires auto-immunes et du rejet de greffe
US10975122B2 (en) 2014-11-25 2021-04-13 Technion Research & Development Foundation Limited Epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection
WO2020160560A3 (fr) * 2019-02-01 2020-09-17 Novarock Biotherapeutics, Ltd. Anticorps anti-claudine 18 et leurs méthodes d'utilisation
CN113645996A (zh) * 2019-02-01 2021-11-12 新石生物制药有限公司 抗claudin 18抗体及其使用方法
US11407828B2 (en) 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
CN113645996B (zh) * 2019-02-01 2024-04-02 新石生物制药有限公司 抗claudin 18抗体及其使用方法

Similar Documents

Publication Publication Date Title
US11572410B2 (en) Neutralization of inhibitory pathways in lymphocytes
US20210122821A1 (en) Neutralization of inhibitory pathways in lymphocytes
US8278423B2 (en) Monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II)
KR102640157B1 (ko) 인간화 항-클라우딘-1 항체 및 이의 용도
KR102574549B1 (ko) 항-fam19a5 항체 및 이의 용도
CN109206516A (zh) 抗IL-23p19抗体
HUE033803T2 (en) Therapeutic use of a specific ligand in MSRV-related diseases
KR20210010486A (ko) 암의 치료
KR20200133233A (ko) 두부경부암의 치료
WO2021070883A1 (fr) Anticorps de liaison au ntcp humain pouvant inhiber l'infection par le virus de l'hépatite b (vhb) d'hépatocytes humains
WO2011086001A1 (fr) Anticorps pour le traitement du vhc
EP4245772A1 (fr) Anticorps anti-nétrine-1 pour traiter l'inflammation du foie
JP7496138B2 (ja) 抗ｆａｍ１９ａ５抗体及びその用途
JP2022550325A (ja) 抗ミュラー管抑制物質抗体およびその使用
CN118103071A (zh) Herv-k抗体治疗剂
EA043381B1 (ru) Антитела к fam19a5 и их применение

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11700616

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19/10/2012)

122 Ep: pct application non-entry in european phase

Ref document number: 11700616

Country of ref document: EP

Kind code of ref document: A1